About this trial

The goal of this randomised controlled trial is to compare the cumulative fluid balance over the first 72 h following inclusion guided by mVExUS versus standard of care in critically ill patients with acute kidney injury receiving CRKT . It will also compare the proportion of CRRT-related complications-including intradialytic hypotension and arrhythmias-between patients managed with mVExUS-guided fluid management and those receiving standard care.

The main questions it aims to answer are:

Does fluid removal rate guided by mVExUS will reduce cumulative fluid balance over the course of the first 72 h of CRRT in ICU patients compared to standard care

Participants will:

Get fluid assessment by mVExUS protocol or a strandard care every 8 hours for 72 hours

Eligibility criteria

Qualifiers

Adults (≥ 18 years of age)

Admitted to ICU

Acute kidney injury by KDIGO criteria

Serum potassium ≥ 6.0 mmol/L, or

Disqualifiers

Refuse to participate

Previous diagnosis of end-stage kidney disease (ESKD) currently on kidney replacement therapy

Kidney transplant recipient

Receive RRT before ICU admission within 90 days

Trial design

Treatments tested in this trial

  • mVExUS-guided fluid management

Treatment groups

126 Participants
are divided into 2 treatment groups

Locations

This trial has no locations

Sponsors and collaborators

Chulalongkorn University

Lead sponsor